Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Hossein Ardeschir Ghofrani"'
Autor:
Olivier Sitbon, Marius M. Hoeper, Gérald Simonneau, Kelly Chin, Lewis J. Rubin, Sean Gaine, Hossein Ardeschir Ghofrani, Richard N. Channick, R Preiss, Victor F. Tapson, Irene Lang, Rafael Sauter, Vallerie V. McLaughlin, Nazzareno Galiè
Publikováno v:
Chest. 160:277-286
Background Early initiation of pulmonary arterial hypertension (PAH) therapies is associated with improved long-term outcomes, yet data on the early use of prostacyclin pathway agents are limited. In these post hoc analyses of the Prostacyclin (PGI2)
Autor:
Victor F. Tapson, Irene M. Lang, Camille Du Roure, Kelly Chin, Olivier Sitbon, Stephan Rosenkranz, Bartosz Jenner, Marius M. Hoeper, Nazzareno Galiè, Lewis J. Rubin, Sean Gaine, Richard N. Channick, Vallerie V. McLaughlin, Hossein Ardeschir Ghofrani
Publikováno v:
Eur J Heart Fail
AIMS: The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0696c1eb76f5b28076d1b62d06c6cdc
https://hdl.handle.net/11585/852846
https://hdl.handle.net/11585/852846
Autor:
Nazzareno Galiè, Lilla Di Scala, Marius M. Hoeper, Raymond L. Benza, Vallerie V. McLaughlin, Lewis J. Rubin, Olivier Sitbon, Sean Gaine, Richard N. Channick, Hossein Ardeschir Ghofrani, R Preiss, Gérald Simonneau, Victor F. Tapson, Irene M. Lang, Kelly Chin
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:300-309
BACKGROUND: Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach (number of low-risk criteria based on the European Society of Cardiology and European Respiratory Society guide
Autor:
Marius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, Sung-A Chang, Paul A Corris, J Simon R Gibbs, Ekkehard Grünig, Pavel Jansa, James R Klinger, David Langleben, Vallerie V McLaughlin, Gisela M B Meyer, Jaquelina Ota-Arakaki, Andrew J Peacock, Tomás Pulido, Stephan Rosenkranz, Carmine Dario Vizza, Anton Vonk-Noordegraaf, R James White, Mikyung Chang, Frank Kleinjung, Christian Meier, Karen Paraschin, Hossein Ardeschir Ghofrani, Gérald Simonneau, H Olschewski, M Delcroix, M Andrade-Lima, R de Amorim Corrêac, F Figueiredo Campos, J Ota Arakaki, G Meyer, R De Souza, D Langleben, H Al-Hiti, P Jansa, S Mellemkjær, F Bauer, D Montani, G Simonneau, D Drömann, H-A Ghofrani, E Grünig, M Halank, M Held, MM Hoeper, H Klose, N Kneidinger, H Leuchte, C Opitz, S Rosenkranz, H Wilkens, H Wirtz, H Karvounis, G Pitsiou, S Orfanos, M D'Alto, S Ghio, CD Vizza, P Vitulo, T Nakayama, H Maki, S Tatebe, M de los Rios Ibarra, T Pulido, A Van Dijk, A Vonk-Noordegraaf, T Roleder, G Castro, MJ Loureiro, S Robalo-Martins, JA Barberá, M Lázaro, GM Perez-Penate, A Román, C-C Cheng, C-H Hsu, H-H Hsu, E Atahan, N Mogulkoc Bishop, NG Okumus, Z Onen, H-J Chang, S-A Chang, J-S Lee, H-K Kim, JG Coghlan, PA Corris, AC Church, R Condliffe, JSR Gibbs, AJ Peacock, S Wort, R Allen, S Allen, R Awdish, RL Benza, S DeSouza, J Feldman, S Johri, JR Klinger, D Layish, J McConnell, VV McLaughlin, C Migliore, F Rahaghi, F Rischard, I Robbins, L Satterwhite, T Shah, R Sulica, RJ White
Publikováno v:
The Lancet Respiratory Medicine, 9(6), 573-584. Elsevier Limited
Hoeper, M M, Al-Hiti, H, Benza, R L, Chang, S-A, Corris, P A, Gibbs, J S R, Grünig, E, Jansa, P, Klinger, J R, Langleben, D, McLaughlin, V V, Meyer, G M B, Ota-Arakaki, J, Peacock, A J, Pulido, T, Rosenkranz, S, Vizza, C D, Vonk-Noordegraaf, A, White, R J, Chang, M, Kleinjung, F, Meier, C, Paraschin, K, Ghofrani, H A, Simonneau, G & The REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE) : a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
Hoeper, M M, Al-Hiti, H, Benza, R L, Chang, S-A, Corris, P A, Gibbs, J S R, Grünig, E, Jansa, P, Klinger, J R, Langleben, D, McLaughlin, V V, Meyer, G M B, Ota-Arakaki, J, Peacock, A J, Pulido, T, Rosenkranz, S, Vizza, C D, Vonk-Noordegraaf, A, White, R J, Chang, M, Kleinjung, F, Meier, C, Paraschin, K, Ghofrani, H A, Simonneau, G & The REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE) : a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
BACKGROUND: Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56129be8d7d9bbfecf556d9b7ae7f504
https://research.vumc.nl/en/publications/422b5ce8-53f9-4f2f-8e03-8a80ae3dd2b8
https://research.vumc.nl/en/publications/422b5ce8-53f9-4f2f-8e03-8a80ae3dd2b8
Autor:
Clemens Ruppert, Friedrich Grimminger, Moritz Christian Neubauer, Astrid Weiss, Ralph T. Schermuly, Beate Christiane Schlueter, Nelli Baal, Peter Dorfmüller, Werner Seeger, Dinesh Yerabolu, Hossein Ardeschir Ghofrani, Lavinia Neubert, Baktybek Kojonazarov, Norbert Weissmann, Soni Savai Pullamsetti, Danny Jonigk
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-17 (2019)
Nature Communications
Nature Communications
Pulmonary arterial hypertension (PAH) is a devastating disease with poor prognosis and limited therapeutic options. We screened for pathways that may be responsible for the abnormal phenotype of pulmonary arterial smooth muscle cells (PASMCs), a majo
Autor:
Norbert Weissmann, Ralph T. Schermuly, Friedrich Grimminger, Aleksandar Petrovic, Baktybek Kojonazarov, Marc Iglarz, Argen Mamazhakypov, Ingrid Fleming, Jochen Wilhelm, Werner Seeger, Christina Vroom, Hossein Ardeschir Ghofrani, Soni Savai Pullamsetti, Sven Zukunft, Astrid Weiß, Akylbek Sydykov, Djuro Kosanovic
Publikováno v:
Pulmonary Circulation
Pulmonary Circulation, Vol 10 (2020)
Pulmonary Circulation, Vol 10 (2020)
Pulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investi
Autor:
Nick H. Kim, Eckhard Mayer, Andrea Maria D'Armini, Hossein Ardeschir Ghofrani, Gérald Simonneau
Publikováno v:
Respiratory medicine. 177
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by obstruction of the pulmonary vasculature, leading to increased pulmonary vascular resistance and ultimately right ventricular failure, the leading cause of death in non-operated patie
Autor:
Marius M. Hoeper, Sean Gaine, L Di Scala, Richard N. Channick, I. Lang, N Galie, O. Sitbon, R Preiss, Hossein Ardeschir Ghofrani, Lewis J. Rubin, Vallerie V. McLaughlin, G. Simonneau, Victor F. Tapson, K. Chin
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Autor:
Bartosz Jenner, Vallerie V. McLaughlin, G. Simonneau, I. Lang, Hossein Ardeschir Ghofrani, Stephan Rosenkranz, Marius M. Hoeper, N Galie, Lewis J. Rubin, O. Sitbon, R Preiss, Victor F. Tapson, Sean Gaine, Richard N. Channick, K. Chin
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Autor:
Norbert Weissmann, Miklós Geiszt, Susan Scheibe, Mariola Bednorz, Christina A. Eichstaedt, Marija Gredic, Ekkehard Grünig, Simone Kraut, Niklas Müller, Hossein Ardeschir Ghofrani, Natascha Sommer, Nirmal Parajuli, Ralph T. Schermuly, Christine Veith, Werner Seeger, Friedrich Grimminger, Stefan Hadzic, Fenja Knoepp, Athanasios Fysikopoulos, Giulia K. Buchmann, Oleg Pak, Peter Dorfmüller, Flávia Rezende, Jochen Wilhelm, Peter Jaksch, Alexandra Pichl, Matthias Hecker, Katrin Schröder, Andreas Hecker, Srikanth Karnati, Winfried Padberg, Baktybek Kojonazarov, Cheng-Yu Wu, Stefan Gattenlöhner, Zeki I. Kanbagli, Ralf P. Brandes, Andreas Günther, Eveline Baumgart-Vogt, Ingrid Henneke, Claus Vogelmeier, Ilka Wittig, Walter Klepetko, Michael Seimetz, Katrin Hinderhofer
Publikováno v:
Nature metabolism. 2(6)
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and death worldwide. Peroxynitrite, formed from nitric oxide, which is derived from inducible nitric oxide synthase, and superoxide, has been implicated in the development of